Cardiovascular Diseases, HIV/AIDS, Platelet Aggregation, Spontaneous
Conditions
Brief summary
This is a small observational study aimed at observing differences in platelet function in HIV patients on abacavir versus tenofovir based anti-HIV drugs. There is some correlation between platelet activation and cardiovascular disease- this study will act as a pilot to see if platelet activation among abacavir users may explain the correlation between abacavir and cardiovascular disease in HIV positive patients. This study will enroll 44 participants total; 22 on abacavir-based treatment, 22 on tenofovir-based treatment. There is only one study visit which includes a blood draw, physical assessment, and review of medical history.
Interventions
DIAGNOSTIC_TESTPlatelet aggregation
Platelet aggregation
Sponsors
University of California, Los Angeles
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV positive * Stable antiretroviral regimen for \> 3months containing either abacavir or tenofovir * Suppressed HIV viral load
Exclusion criteria
* Current cigarette smoking * Pre-existing platelet disorder * current or recent (last 6 months) antiplatelet therapy * pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Platelet aggregation | At screening visit | Degree of platelet aggregation in response to adenosine diphosphate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Markers of coagulation | At screening visit | sGPVI |
| Plasma Markers of Coagulation | At screening visit | sPSelectin |
| Plasma markers of endothelial function | At screening visit | sICAM |
Countries
United States
Outcome results
None listed